Drugs

A carefully crafted resource to ensure that oncology professionals stay up-to-date with the most recent drug updates and FDA approvals. Here, you'll discover a collection of vital information, enabling you to make well-informed choices and provide advanced care to your patients. Keep up with the ever-changing world of oncology treatments with our extensive updates, guaranteeing that your practice stays at the forefront.

To view current and resolved drug shortages and discontinuations reported to the FDA, click here.

• Geron's RYTELO™ (imetelstat) Received Permanent J-Code (Effective Janaury 1, 2025)

We are pleased to share the permanent J-code for RYTELO™ (imetelstat). For dates of service on or after January 1, 2025, use J-code J0870 when submitting claims for RYTELO. The permanent J-code enables providers and office staff to code with specificity, for claims processing purposes, after RYTELO is administered to a patient.1

Permanent J-Code	Description	Sites of Care
J0870	Injection, imetelstat, 1 mg	All

 

10-digit NDC2	11-digit NDC	Vial Size	Billing Units
82959-112-01	82959-0112-01	One RYTELO 47 mg single-dose vial	47
82959-111-01	82959-0111-01	One RYTELO 188 mg single-dose vial	188

Please consider updating your billing software to reflect the permanent J-code J0870, units: 1 unit per 1 mg, and expected reimbursement for use on or after January 1. 2025.

Click here to learn more about RYTELO.

Please see full Prescribing Information, including Medication Guide.

• Amgen's New J-Code & Dose Dexcriptor / Billing Unit for Nplate

• AstraZeneca's TRUQAP Blister Pack Launch

AstraZeneca is thrilled to share late-breaking news regarding the availability of TRUQAP. The AstraZeneca Trade Ops team has been hard at work and is happy to report that TRUQAP blister packs are available for ordering from the Big 3 Specialty Distributors starting Monday, October 28.

1. MCKESSON – Product is available to customers. Should a customer not see the product visible in the ordering system, please ask that they call their purchasing contact at McKesson.
2. CENCORA – Product is available to customers via their portal.
3. CARDINAL – Product is available to customers via their portal.

Pharmaceutical Buyer Letter

Notice To 340 B Covered Entities Regarding Truqap 

Blister Pack Leave Behind

• Results of Aveo's Phase 3 TiNivo-2 Study

• NTAP Now Available for Johnson & Johnson's TALVEY® (talquetamab-tgvs)

Johnson & Johnson Health Care Systems Inc. submitted an application to the Centers for Medicare and Medicaid Services (CMS) for a New Technology Add-On Payment (NTAP) for TALVEY® for Federal Fiscal Year (FFY) 2025. On August 1, 2024, CMS approved 5 NTAP applications for technologies, including the application for TALVEY®, in the Inpatient Prospective Payment System final rule.

Effective October 1, 2024, TALVEY® is eligible for a New Technology Add-On Payment (NTAP).

For more details related to the NTAP now available for TALVEY®, please click here.